Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10006800HBVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TVIS30084720HIVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TVIS30063823HIVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TVIS30063824HIVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TVIS30063825HIVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TVIS20060150HPVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TVIS20059200HPVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TVIS20018080HPVENSG00000145888.11protein_codingGLRA1NoNo2741P23415
Q14C71
TCGA Plot Options
Drug Information
GeneGLRA1
DrugBank IDDB01956
Drug NameTaurine
Target IDBE0000433
UniProt IDP23415
Regulation Typeagonist
PubMed IDs15081878
CitationsJensen AA, Kristiansen U: Functional characterisation of the human alpha1 glycine receptor in a fluorescence-based membrane potential assay. Biochem Pharmacol. 2004 May 1;67(9):1789-99.
GroupsApproved; Nutraceutical
Direct ClassificationOrganosulfonic acids
SMILESNCCS(O)(=O)=O
PathwaysCongenital Bile Acid Synthesis Defect Type II; Familial Hypercholanemia (FHCA); Bile Acid Biosynthesis; Zellweger Syndrome; Congenital Bile Acid Synthesis Defect Type III; Taurine and Hypotaurine Metabolism; 27-Hydroxylase Deficiency; Cerebrotendinous Xanthomatosis (CTX)
PharmGKBPA451590
ChEMBLCHEMBL239243